Observation of other's preferential treatment as a constructive catalyst for improved repatronize intentions

Observing others receive preferential treatment has been found to provoke bystanders' negative reactions. However, seeing others treated better may also inspire bystanders to increase their repatronize intentions. Drawing upon theories of social comparison and goal-setting, this study investigates the condition when watching another's preferential treatment acts as a catalyst to enhance bystanders' repatronize intentions and the mechanism by which the constructive effect appears. The results indicate that when bystanders witness similar others' preferential treatment and believe that they can attain comparable treatment, their goal-setting motivation is more activated and consequently they are more committed to goal-relevant behavior (i.e., repatronize intentions).     

自动岩土工程勘察与地基处理问题及解决对策

在建筑工程项目建设过程中,岩土工程勘察为地基设计提供了基础支持,能够为建筑物基础设计、地基处理、施工提供工程地质资料和技术参数。但是,很多建筑企业不注重岩土工程勘察工作,导致实际勘察工作中出现了一系列问题,相关部门需要深入分析这些问题,针对岩土工程勘察和地基处理问题制定相应的解决方法,论文主要分析了岩土工程勘察与地基处理问题及解决对策。     

Estimating the potential impact of requiring a stand-alone board-level risk committee

Motivated by the requirement under the Dodd-Frank Act that all large bank holding companies create a stand-alone, board-level risk committee, this paper investigates the association between such a committee and regulatory risk both before and during the financial crisis. I focus the analysis on the set of banks that did not have a risk committee in place prior to the Dodd-Frank Act, as these are the banks that were most affected by the regulation. I find that matched control banks with a risk committee in place had higher capital ratios during the financial crisis, but lower capital ratios during more stable economic conditions relative to the banks without a risk committee. This paper contributes to the literature by narrowly investigating the effects a board-level risk committee, by focusing on a risk measure that is of interest to the regulators who implemented the new regulation, and by documenting that this association changes over time which highlights the importance of estimating the effects of new regulations across different economic conditions.     

我国碳排放交易会计问题研究

从碳排放交易所涉及重点排放企业的角度出发,通过分析我国碳排放交易市场的现状,借鉴相关的研究与规范,就碳排放配额的会计确认问题、碳排放权交易的会计处理问题、企业碳排放相关的会计信息披露问题进行研究分析,提出了碳排放交易的会计处理的意见和建议。     

建筑施工中的地基施工处理技术分析

在近几年的发展中,建筑工程在我国的发展越来越完善,人们在建筑上的需求逐渐增高,不仅注重建筑的质量,在美观上也要更加有创新性。以此,为加强对建筑工程的实施,地基施工处理技术是建筑的重要组成部分,在提升建筑工程发展时,地基施工处理技术起着至关重要的作用,这直接影响着整个工程的发展。     

山岭隧道洞口浅层滑坡处治关键技术研究

受地形地质条件、工程经济以及勘察深度等因素的制约,山岭重丘区隧道不可避免地会受到各种不良地质灾害的影响.为解决隧道穿越洞口浅埋段滑坡体的施工安全问题,以乐业至百色高速公路永乐隧道工程为研究背景,针对其地形地质条件及滑坡体情况,结合洞内变形与滑坡体变形相互作用机理,对隧道穿越洞口浅埋段滑坡体施工关键技术进行研究,并针对性地提出"洞外加固处治+洞内严格控制沉降"的综合处治方案.实践结果表明,本隧道工程穿越洞口浅层滑坡体的施工过程安全顺利,采取的施工控制措施方案实施效果良好.     

On the treatment of persons with disabilities in organizations: A review and research agenda

Human resource practitioners play a crucial role in promoting equitable treatment of persons with disabilities, and practitioner's decisions should be guided by solid evidence‐based research. We offer a systematic review of the empirical research on the treatment of persons with disabilities in organizations, using Stone and Colella's seminal theoretical model of the factors influencing the treatment of persons with disabilities in work organizations, to ask: What does the available research reveal about workplace treatment of persons with disabilities, and what remains understudied? Our review of 88 empirical studies from management, rehabilitation, psychology, and sociology research highlights seven gaps and limitations in extant research: (a) implicit definitions of workplace treatment; (b) neglect of national context variation; (c) missing differentiation between disability populations; (d) overreliance on available data sets; (e) predominance of single‐source, cross‐sectional data; (f) neglect of individual differences and identities in the presence of disability; and (g) lack of specificity on underlying stigma processes. To support the development of more inclusive workplaces, we recommend increased research collaborations between human resource researchers and practitioners on the study of specific disabilities and contexts, and efforts to define and expand notions of treatment to capture more nuanced outcomes.     

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results

Aims: The EINSTEIN-Extension trial (EINSTEIN-EXT) found that continued treatment with rivaroxaban for an additional 6 or 12 months (vs placebo) after 6–12 months of initial anticoagulation significantly reduced the risk of recurrent venous thromboembolism (VTE) with a small non-significant increased risk of major bleeding (none fatal or in critical site). This study aimed to compare total healthcare cost between rivaroxaban and placebo, based on the EINSTEIN-EXT event rates.

Methods: Total healthcare cost was calculated as the sum of treatment and clinical event costs from a US managed care perspective. Treatment duration and event rates were obtained from the EINSTEIN-EXT study. Adjustment on treatment duration was made by assuming a 10% non-adherence rate. Drug costs were based on wholesale acquisition costs. Cost estimates for clinical events (i.e. recurrent deep vein thrombosis [DVT], recurrent pulmonary embolism, major bleeding, clinically relevant non-major bleeding) were determined from the literature. Results were examined over a ±20% range of each cost component and over 95% confidence intervals (CIs) of event rate differences in deterministic (one-way) and probabilistic sensitivity analyses (PSA).

Results: Total healthcare cost was $1,454 lower for rivaroxaban-treated (vs placebo-treated) patients in the base-case, with a lower clinical event cost fully offsetting drug cost. The cost savings of recurrent DVT alone (–$3,102) was greater than drug cost ($2,723). Total healthcare cost remained lower for rivaroxaban in the majority (73%) of PSA (cost difference [95% CI]?=?–$1,454 [–$2,396, $1,231]).

Limitations: This study was conducted over the 1-year observation period of the EINSTEIN-EXT trial, which limited “real-world” applicability and examination of long-term economic impact. Assumptions on drug and clinical event costs were US-based and, thus, not applicable to other healthcare systems.

Conclusions: Total healthcare costs were estimated to be lower for patients continuing rivaroxaban therapy compared to those receiving placebo in VTE patients who had completed 6–12 months of VTE treatment.     

医疗器械产业创新集群的现状及路径研究——以宁波市为例

产业集群能提高企业、区域和国家竞争力。当前以产业创新集群为代表的新一轮产业集群正在各地兴起。通过行业融合、知识外溢和集体行动，产业创新集群促进相关企业和支持性机构紧密互动而加速创新。医疗器械产业科技含量高，创新性强，是当前少数几个涉及学科最多的产业之一。以医疗器械产业为研究对象，从集群和区域创新发展的要义出发，挑选宁波地区的医疗器械行业，测算其行业集中度和产业集群效应，提出提升医疗器械行业集群度，激发产业创新集群活力的对策建议。